---
document_datetime: 2025-12-29 11:59:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/truxima.html
document_name: truxima.html
version: success
processing_time: 0.1194666
conversion_datetime: 2025-12-30 11:29:08.93247
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Truxima

[RSS](/en/individual-human-medicine.xml/66200)

##### Authorised

This medicine is authorised for use in the European Union

rituximab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Truxima](#news-on)
- [Related content](#related-content-640)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Truxima is a medicine used to treat the following blood cancers and inflammatory conditions:

- follicular lymphoma and diffuse large B cell non-Hodgkin's lymphoma (two types of non-Hodgkin's lymphoma, a blood cancer)
- chronic lymphocytic leukaemia (CLL, another blood cancer affecting white blood cells)
- severe rheumatoid arthritis (an inflammatory condition of the joints)
- granulomatosis with polyangiitis (GPA or Wegener's granulomatosis) and microscopic polyangiitis (MPA), which are inflammatory conditions of the blood vessels
- moderate to severe pemphigus vulgaris, an autoimmune disease characterised by widespread blistering and erosion of the skin and mucous membranes (moist body surfaces, such as the lining of the mouth). 'Autoimmune' means that the disease is caused by the immune system (the body's natural defences) attacking the body's own cells.

Depending on the condition it is used to treat, Truxima may be given on its own, or with chemotherapy (other cancer medicines) or medicines used for inflammatory disorders (methotrexate or a corticosteroid). Truxima contains the active substance rituximab.

Truxima is a 'biosimilar medicine'. This means that Truxima is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Truxima is MabThera. For more information on biosimilar medicines, see [here](/en/biosimilar-medicines-overview) .

Expand section

Collapse section

## How is Truxima used?

Truxima can only be obtained with a prescription. It is given by infusion (drip) into a vein. Before each infusion, the patient should be given an antihistamine (to prevent allergic reactions) and an anti-pyretic (a medicine to prevent fever). Depending on the condition being treated, patients may receive other medicines as well. In addition, the medicine should be given under the close supervision of an experienced healthcare professional and in a place where facilities for resuscitating patients are immediately available.

For more information about using Truxima, see the package leaflet or contact your doctor or pharmacist.

## How does Truxima work?

The active substance in Truxima, rituximab, is a monoclonal antibody (a type of protein) designed to recognise and attach to a protein called CD20 present on the surface of B lymphocytes (types of white blood cells). When rituximab attaches to CD20, it causes the death of B lymphocytes, which helps in lymphoma and CLL (where B-lymphocytes have become cancerous) and in rheumatoid arthritis (where B lymphocytes are involved in joint inflammation). In GPA and MPA, destroying the B lymphocytes lowers the production of antibodies thought to play an important role in attacking the blood vessels and causing inflammation.

## What benefits of Truxima have been shown in studies?

Extensive laboratory studies comparing Truxima with MabThera have shown that rituximab in Truxima is highly similar to rituximab in MabThera in terms of structure, purity and biological activity.

Truxima has been compared with MabThera given into a vein in a study involving 372 patients with active rheumatoid arthritis. The study showed that Truxima and MabThera led to similar levels of rituximab in the blood. In addition, the two medicines had comparable effects on arthritis symptoms: after 24 weeks, the proportion of patients with a 20% improvement in symptom score (called ACR20) was 74% (114 of 155 patients) with Truxima and 73% (43 of 59 patients) with MabThera. Supportive studies in patients with rheumatoid arthritis and in patients with advanced follicular lymphoma also indicated that the medicines produced similar responses.

Because Truxima is a biosimilar medicine, the studies on effectiveness and safety carried out for MabThera do not all need to be repeated for Truxima.

## What are the risks associated with Truxima?

The safety of Truxima has been evaluated and, on the basis of all the studies, its side effects are considered comparable to those of the reference medicine MabThera.

The most common side effects with rituximab are reactions related to the infusion (such as fever, chills and shivering) which occur in the majority of patients after the first infusion. The risk of such reactions decreases with subsequent infusions. The most common serious side effects are infusion reactions, infections (which may affect more than half of all patients) and heart-related problems. Other serious side effects include hepatitis B reactivation (return of previous active liver infection with hepatitis B virus) and a rare severe infection known as progressive multifocal leukoencephalopathy (PML). For the full list of side effects of Truxima, see the package leaflet.

Truxima must not be used in people who are hypersensitive (allergic) to rituximab, mouse proteins or any of the other ingredients. It must also not be used in patients with a severe infection or a severely weakened immune system. Patients with rheumatoid arthritis, GPA, MPA or pemphigus vulgaris must also not receive Truxima if they have severe heart problems.

## Why is Truxima authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Truxima has a highly similar structure, purity and biological activity to MabThera and is distributed in the body in the same way. In addition, a study comparing Truxima to MabThera in rheumatoid arthritis adult patients showed that both medicines are similarly effective.

All these data were considered sufficient to conclude that Truxima will behave in the same way as MabThera in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for MabThera, the benefits of Truxima outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Truxima?

The company marketing Truxima will provide doctors and patients using the medicine for non-cancer conditions with educational material on the need to give the medicine where facilities for resuscitation are available and on the risk of infection, including PML. Patients are also to receive an alert card, which they are to carry at all times, instructing them to contact their doctor immediately if they have any of the listed symptoms of infection.

Doctors prescribing Truxima for cancer will be provided with educational material reminding them of the need to use the medicine only by infusion into a vein.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Truxima have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Truxima are continuously monitored. Side effects reported with Truxima are carefully evaluated and any necessary action taken to protect patients.

## Other information about Truxima

Truxima received a marketing authorisation valid throughout the EU on 17 February 2017.

The full EPAR for Truxima can be found on the Agency's website: [ema.europa.eu/medicines/human/EPAR/truxima](/en/medicines/human/EPAR/truxima) .

This overview was last updated in 10-2020.

Truxima : EPAR - Medicine overview

Reference Number: EMA/413553/2019

English (EN) (132.29 KB - PDF)

**First published:** 08/03/2017

**Last updated:** 05/09/2022

[View](/en/documents/overview/truxima-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-137)

български (BG) (157.42 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/bg/documents/overview/truxima-epar-medicine-overview_bg.pdf)

español (ES) (132.89 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/es/documents/overview/truxima-epar-medicine-overview_es.pdf)

čeština (CS) (176.5 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/cs/documents/overview/truxima-epar-medicine-overview_cs.pdf)

dansk (DA) (130.96 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/da/documents/overview/truxima-epar-medicine-overview_da.pdf)

Deutsch (DE) (135.94 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/de/documents/overview/truxima-epar-medicine-overview_de.pdf)

eesti keel (ET) (121.01 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/et/documents/overview/truxima-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.25 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/el/documents/overview/truxima-epar-medicine-overview_el.pdf)

français (FR) (133.87 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/fr/documents/overview/truxima-epar-medicine-overview_fr.pdf)

hrvatski (HR) (155.3 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/hr/documents/overview/truxima-epar-medicine-overview_hr.pdf)

italiano (IT) (131.08 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/it/documents/overview/truxima-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (153.37 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/lv/documents/overview/truxima-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (155.87 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/lt/documents/overview/truxima-epar-medicine-overview_lt.pdf)

magyar (HU) (155.73 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/hu/documents/overview/truxima-epar-medicine-overview_hu.pdf)

Malti (MT) (158.13 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/mt/documents/overview/truxima-epar-medicine-overview_mt.pdf)

Nederlands (NL) (132.71 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/nl/documents/overview/truxima-epar-medicine-overview_nl.pdf)

polski (PL) (157.81 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/pl/documents/overview/truxima-epar-medicine-overview_pl.pdf)

português (PT) (133.54 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/pt/documents/overview/truxima-epar-medicine-overview_pt.pdf)

română (RO) (154.3 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/ro/documents/overview/truxima-epar-medicine-overview_ro.pdf)

slovenčina (SK) (156.48 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/sk/documents/overview/truxima-epar-medicine-overview_sk.pdf)

slovenščina (SL) (155.21 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/sl/documents/overview/truxima-epar-medicine-overview_sl.pdf)

Suomi (FI) (129.69 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/fi/documents/overview/truxima-epar-medicine-overview_fi.pdf)

svenska (SV) (130.21 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

05/09/2022

[View](/sv/documents/overview/truxima-epar-medicine-overview_sv.pdf)

Truxima : EPAR - Risk management plan

English (EN) (865.28 KB - PDF)

**First published:** 21/08/2025

[View](/en/documents/rmp/truxima-epar-risk-management-plan_en.pdf)

## Product information

Truxima : EPAR - Product information

English (EN) (868.58 KB - PDF)

**First published:** 08/03/2017

**Last updated:** 29/09/2025

[View](/en/documents/product-information/truxima-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-90)

български (BG) (1.04 MB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/bg/documents/product-information/truxima-epar-product-information_bg.pdf)

español (ES) (890.78 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/es/documents/product-information/truxima-epar-product-information_es.pdf)

čeština (CS) (1 MB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/cs/documents/product-information/truxima-epar-product-information_cs.pdf)

dansk (DA) (788.7 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/da/documents/product-information/truxima-epar-product-information_da.pdf)

Deutsch (DE) (840.21 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/de/documents/product-information/truxima-epar-product-information_de.pdf)

eesti keel (ET) (730.69 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/et/documents/product-information/truxima-epar-product-information_et.pdf)

ελληνικά (EL) (1.1 MB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/el/documents/product-information/truxima-epar-product-information_el.pdf)

français (FR) (899.08 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/fr/documents/product-information/truxima-epar-product-information_fr.pdf)

hrvatski (HR) (907.39 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/hr/documents/product-information/truxima-epar-product-information_hr.pdf)

íslenska (IS) (748.58 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/is/documents/product-information/truxima-epar-product-information_is.pdf)

italiano (IT) (975.02 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/it/documents/product-information/truxima-epar-product-information_it.pdf)

latviešu valoda (LV) (1.03 MB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/lv/documents/product-information/truxima-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.04 MB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/lt/documents/product-information/truxima-epar-product-information_lt.pdf)

magyar (HU) (1.01 MB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/hu/documents/product-information/truxima-epar-product-information_hu.pdf)

Malti (MT) (1.07 MB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/mt/documents/product-information/truxima-epar-product-information_mt.pdf)

Nederlands (NL) (871.61 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/nl/documents/product-information/truxima-epar-product-information_nl.pdf)

norsk (NO) (862.81 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/no/documents/product-information/truxima-epar-product-information_no.pdf)

polski (PL) (1.23 MB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/pl/documents/product-information/truxima-epar-product-information_pl.pdf)

português (PT) (852.72 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/pt/documents/product-information/truxima-epar-product-information_pt.pdf)

română (RO) (1019.67 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/ro/documents/product-information/truxima-epar-product-information_ro.pdf)

slovenčina (SK) (965.62 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/sk/documents/product-information/truxima-epar-product-information_sk.pdf)

slovenščina (SL) (928.94 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/sl/documents/product-information/truxima-epar-product-information_sl.pdf)

Suomi (FI) (903.5 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/fi/documents/product-information/truxima-epar-product-information_fi.pdf)

svenska (SV) (846.86 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

29/09/2025

[View](/sv/documents/product-information/truxima-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000290253 25/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Truxima : EPAR - All Authorised presentations

English (EN) (16.73 KB - PDF)

**First published:** 08/03/2017

**Last updated:** 28/05/2025

[View](/en/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-726)

български (BG) (42.42 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/bg/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.47 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/es/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_es.pdf)

čeština (CS) (36.6 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/cs/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.96 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/da/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.26 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/de/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (16.66 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/et/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.44 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/el/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_el.pdf)

français (FR) (16.94 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/fr/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.17 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/hr/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.78 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/is/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.1 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/it/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (40.12 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/lv/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.47 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/lt/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.12 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/hu/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (39.21 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/mt/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (16.25 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/nl/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.93 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/no/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.12 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/pl/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.2 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/pt/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.16 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/ro/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.28 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/sk/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.56 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/sl/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.84 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/fi/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.22 KB - PDF)

**First published:**

08/03/2017

**Last updated:**

28/05/2025

[View](/sv/documents/all-authorised-presentations/truxima-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Truxima Active substance rituximab International non-proprietary name (INN) or common name rituximab Therapeutic area (MeSH)

- Lymphoma, Non-Hodgkin
- Arthritis, Rheumatoid
- Wegener Granulomatosis
- Leukemia, Lymphocytic, Chronic, B-Cell
- Microscopic Polyangiitis

Anatomical therapeutic chemical (ATC) code L01FA01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Truxima is indicated in adults for the following indications:

**Non-Hodgkin's lymphoma (NHL)**

Truxima is indicated for the treatment of previously untreated patients with stage III IV follicular lymphoma in combination with chemotherapy.

Truxima maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.

Truxima monotherapy is indicated for treatment of patients with stage III IV follicular lymphoma who are chemo resistant or are in their second or subsequent relapse after chemotherapy.

Truxima is indicated for the treatment of patients with CD20 positive diffuse large B cell non Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

**Chronic lymphocytic leukaemia (CLL)**

Truxima in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Truxima or patients refractory to previous Truxima plus chemotherapy.

**Rheumatoid arthritis**

Truxima in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease modifying anti rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.

Truxima has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function, when given in combination with methotrexate.

**Granulomatosis with polyangiitis and microscopic polyangiitis**

Truxima, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).

**Pemphigus vulgaris**

Truxima is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).

## Authorisation details

EMA product number EMEA/H/C/004112

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Celltrion Healthcare Hungary Kft.

1062 Budapest

Opinion adopted 15/12/2016 Marketing authorisation issued 17/02/2017 Revision 26

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Truxima : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (165.43 KB - PDF)

**First published:** 04/02/2025

**Last updated:** 29/09/2025

[View](/en/documents/procedural-steps-after/truxima-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf-0)

Truxima : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (218.22 KB - PDF)

**First published:** 11/05/2017

**Last updated:** 04/02/2025

[View](/en/documents/procedural-steps-after/truxima-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Trixuma-H-C-PSUSA-00002652-202211 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/540498/2023

English (EN) (130.64 KB - PDF)

**First published:** 29/11/2023

[View](/en/documents/scientific-conclusion/trixuma-h-c-psusa-00002652-202211-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Truxima : EPAR-H-C-PSUSA-00002652-202111 - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Adopted

Reference Number: EMA/592634/2022

English (EN) (117.16 KB - PDF)

**First published:** 05/09/2022

[View](/en/documents/scientific-conclusion/truxima-epar-h-c-psusa-00002652-202111-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Truxima : EPAR-H-C-PSUSA-00002652-202011- Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Adopted

Reference Number: EMA/403185/2021

English (EN) (122.93 KB - PDF)

**First published:** 26/08/2021

[View](/en/documents/scientific-conclusion/truxima-epar-h-c-psusa-00002652-202011-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Truxima : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/75695/2017

English (EN) (9.32 MB - PDF)

**First published:** 08/03/2017

**Last updated:** 08/03/2017

[View](/en/documents/assessment-report/truxima-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Truxima

Adopted

Reference Number: EMA/CHMP/813387/2016

English (EN) (72.98 KB - PDF)

**First published:** 16/12/2016

**Last updated:** 16/12/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-truxima_en.pdf)

#### News on Truxima

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2016) 16/12/2016

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/09/2025

## Share this page

[Back to top](#main-content)